Theranexus (XPAR:ALTHX) Growth Rank : 0 (As of Jun. 04, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Theranexus Growth Rank?

Theranexus has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Theranexus Growth Rank Related Terms

Thank you for viewing the detailed overview of Theranexus's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Theranexus (XPAR:ALTHX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theranexus SA (XPAR:ALTHX) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

3VG:Germany

Address

60 avenue Rockefeller, Pepiniere Laennec, Lyon, FRA, 69008

Website

https://www.theranexus.com

Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company's therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson's disease, THN201 for the treatment of neurocognitive disorders in Alzheimer's disease and THN101 for neuropathic pain.

Theranexus (XPAR:ALTHX) Headlines

No Headlines